Exogenus T

1 known investors

Exogenus Therapeutics is a biotechnology company developing extracellular vesicle (exosome) technologies for regenerative medicine, with a lead candidate, EXO-101, derived from umbilical cord blood cells for inflammatory and fibrotic diseases. It focuses on the development, manufacturing (in GMP conditions), and commercialization of exosome-based therapeutics.